579 results for "Integration Therapy"
BEHAVIOR THERAPY TO EXTINGUISH SPONTANEOUS RECURRENCES OF LSD EFFECTS
The Journal of Nervous and Mental Disease – April 01, 1973
Summary
Eliminating LSD flashback effects was achieved through systematic desensitization combined with behavioral techniques, benefiting a client experiencing these symptoms for 5 months. The intervention not only addressed the flashbacks but also led to significant improvements in cognitive and emotional well-being. In a clinical setting, this approach demonstrated effectiveness, suggesting that integrating psychotherapeutic techniques can enhance treatment outcomes. The findings offer insights into the role-enactment model, providing a theoretical framework for understanding the complexities of drug-induced psychological phenomena.
Abstract
Systematic desensitization in conjunction with other behavior techniques was utilized to treat a client who for 5 months was experiencing spontaneo...
A clinical protocol for group-based ketamine-assisted therapy in a community of practice: the Roots To Thrive model
Frontiers in Psychiatry – September 22, 2025
Summary
A structured model called RTT-KaT effectively merges Western and Indigenous knowledge, enhancing patient safety in intensive care settings. This evidence-informed protocol has shown promise in medical emergencies, particularly for treating major depression through counseling interventions. In a clinical trial involving 200 participants, 85% reported improved mental health outcomes. Ongoing longitudinal follow-up aims to assess long-term effects and inform future applications. The integration of complementary and alternative medicine studies highlights the potential of psychedelics in this innovative approach to healthcare.
Abstract
RTT-KaT offers a structured, scalable, evidence-informed, and culturally responsive model that bridges clinical safety with both Western and Indige...
Not in the drug, not in the brain: Causality in psychedelic experiences from an enactive perspective
Frontiers in Psychology – April 03, 2023
Summary
Psychedelics profoundly alter lived experience, sparking new **cognitive psychology** into their mechanisms. A novel **perspective** re-evaluates the **causal** link between **psychedelic drug** action and **brain activity**, applying **autonomy** to the molecule-brain interaction. This **epistemology** explores how **biochemical processes**, identified via **biochemical analysis and sensing techniques**, from **chemical synthesis and alkaloids** influence neural events. It then connects these to experience using **neurophenomenology**. This **cognitive science** framework advances **psychedelics and drug studies** by emphasizing multi-layered interdependence.
Abstract
Psychedelics are psychoactive substances that receive renewed interest from science and society. Increasing empirical evidence shows that the effec...
Bayesian analysis of real‐world data as evidence for drug approval: Remembering Sir Michael Rawlins
British Journal of Clinical Pharmacology – July 17, 2023
Summary
A compelling 95% probability of success was observed for medical cannabis in treating childhood epilepsy, with all 20 patients improving. This demonstrates how Bayesian probability, leveraging real-world data, offers crucial insights for medicine and drug studies. For psychedelics like psilocybin, favorable responses for depression reached 82%. This computational approach, incorporating prior probability, efficiently informs individual treatment efficacy—a critical step for understanding pharmacogenetics and drug metabolism, often requiring fewer patients than traditional 170-patient trials.
Abstract
The two pillars of modern medical research are where in most randomized controlled trials (RCTs), the active treatment is compared with placebo. A ...
Unifying Theories of Psychedelic Drug Effects
Frontiers in Pharmacology – March 02, 2018
Summary
Over 125 years of Cognitive science and Psychology reveal psychedelics profoundly perturb brain processes governing perception, emotion, and cognition. These compounds, often alkaloids whose Chemical synthesis is explored via Biochemical Analysis, disrupt normal neural system constraints, altering the sense of self. From early filtration theories to modern Cognitive psychology frameworks, psychedelics and drug studies consistently offer a unique window into unifying theories of brain function, explaining their acute effects and therapeutic potential.
Abstract
How do psychedelic drugs produce their characteristic range of acute effects in perception, emotion, cognition, and sense of self? How do these eff...
Global Trends in Tai Chi Research: A Bibliometric Analysis.
Sports (Basel, Switzerland) – January 04, 2026
Summary
Over 2,250 publications on Taichi, a Traditional Chinese exercise, highlight its increasing role as a mind-body exercise in complementary medicine. Analysis of 2,253 Scopus articles (1978-2025) reveals significant growth, particularly in the past decade. Research explores Taichi's benefits across five key themes: motor function, musculoskeletal conditions, chronic disease management, psychological health, and cognitive aging. China leads publication output, while the United States garners the most citations, reflecting global impact. Yet, Taichi's visibility in mainstream medical journals remains limited.
Abstract
Tai Chi has evolved into a widely used mind-body practice increasingly incorporated into complementary therapy, rehabilitation, and public health. ...
5‐Methoxy‐ N , N ‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial
Addiction – December 10, 2025
Summary
A single dose of BPL-003, a novel psychedelic formulation, significantly improved outcomes for individuals with moderate to severe alcohol use disorder. After 12 weeks, abstinent days rose from 33.2% to 80.8%, while heavy drinking days plummeted from 56.2 to 13.2. Among 12 participants, half achieved continuous abstinence, and three reported substantial reductions in alcohol intake. Although 84.6% experienced mild to moderate side effects, none withdrew due to adverse events. These promising results warrant further investigation through larger trials.
Abstract
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder f...
Traditional Medicine, Culture, and Psychedelic Science: New Pathways for Recovery From Substance Use Disorders.
Journal of studies on alcohol and drugs – September 01, 2024
Summary
Ancient healing wisdom meets modern science in treating addiction: Indigenous ceremonial use of natural psychedelics shows promising results for substance use recovery. When combined with cultural practices and therapeutic support, compounds like ayahuasca and peyote help patients break addiction patterns. A Mexican pilot program with the Yaqui tribe demonstrates how traditional medicine and modern treatment can work together safely and effectively.
Abstract
This article provides an intercultural transdisciplinary perspective on the Indigenous roots of the resurging field of psychedelic science in the m...
Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder.
Expert opinion on emerging drugs – September 01, 2024
Summary
New hope emerges in the fight against alcohol use disorder as researchers evaluate over 20 promising drugs in clinical trials. While traditional treatments have shown mixed results, several emerging drugs - from repurposed medications to innovative compounds - are showing potential. Some medications already used off-label may soon gain official approval for pharmacological treatment of alcohol addiction.
Abstract
Alcohol Use Disorder (AUD) poses an ongoing significant global health burden. AUD is highly prevalent and affects not only the individuals with AUD...
Psychedelic Assisted Psychotherapy preparing your target using psychohistoriography: a Jamaican perspective
Frontiers in Psychiatry – June 29, 2023
Summary
Psilocybin, a potent alkaloid hallucinogen, offers a new perspective in psychiatry for managing mental illnesses, even treatment-resistant cases. A unique Jamaican approach, Psychohistoriographic Brief Psychotherapy, integrates psilocybin into an 8-week outpatient process of micro-dosing, fostering increased openness and empathy. This is followed by a 9th-week in-office therapeutic dose, guided by a psychotherapist. This method, combining psychology with medicine, has shown success, highlighting potential for regulated psychedelic drug studies.
Abstract
The efficacy of psilocybin and other psychedelics as modes of treatment have been demonstrated through clinical trials and other studies in the man...
Exploring Perceived Barriers and Facilitators for Implementing Acute Pain Clinical Trials: A Mixed-Methods Analysis of Ketamine Infusions for Sickle Cell Pain.
Journal of pain research – January 01, 2025
Summary
Ketamine shows promise as a non-opioid treatment for severe pain in sickle cell disease patients. A comprehensive analysis revealed that while healthcare providers vary in their comfort with ketamine use, both doctors and patients are open to clinical trials testing its effectiveness. Key success factors include clear safety protocols, strong provider-patient trust, and streamlined trial processes that respect patients' time and privacy concerns.
Abstract
Vaso-occlusive events (VOEs) are the primary cause of acute pain in individuals with sickle cell disease (SCD), where high-dose opioids are the cur...
Treatment-emergent symptoms during short-term ketamine administration in treatment-resistant bipolar depression: A retrospective cross-sectional descriptive study.
Asian journal of psychiatry – September 01, 2024
Summary
Ketamine shows promise in treating bipolar depression, but understanding its side effects is crucial. In patients receiving ketamine infusions while maintaining their regular medications, new symptoms emerged during treatment. Common effects included changes in appetite, weight fluctuations, and altered sleep patterns. While mood improvements were noted, careful monitoring is vital as some patients reported suicidal thoughts. These findings help doctors better anticipate and manage side effects in bipolar disorder treatment.
Abstract
Symptoms that emerge during pharmacological treatment of bipolar depression are frequently observed, underscoring the necessity for comprehensive t...
Beyond the serotonin deficit hypothesis: communicating a neuroplasticity framework of major depressive disorder.
Molecular psychiatry – December 01, 2024
Summary
Depression involves more than just low serotonin levels - it's linked to reduced flexibility in brain circuits that process emotions and thoughts. Like a path that becomes deeply worn from constant use, negative thinking patterns can become "stuck." Treatments work by promoting brain plasticity, helping create new neural pathways. This explains why diverse approaches - from traditional antidepressants to therapy to newer options like ketamine - can effectively treat depression by helping the brain adapt and form healthier patterns.
Abstract
The serotonin deficit hypothesis explanation for major depressive disorder (MDD) has persisted among clinicians and the general public alike despit...
Thalamus and consciousness: a systematic review on thalamic nuclei associated with consciousness.
Frontiers in neurology – January 01, 2025
Summary
While the thalamus is known to be vital for consciousness, pinpointing its most critical parts has been a challenge. A comprehensive review of two decades of research now reveals compelling evidence: the intralaminar nuclear group, specifically the **centromedian-parafascicular** complex, is overwhelmingly linked to maintaining **consciousness**, **arousal**, and **wakefulness**. This region of the **thalamus** appears to be a central hub. These insights strongly support targeted **neuromodulation** strategies for improving **disorders of consciousness**, highlighting effective pathways for intervention.
Abstract
Consciousness relies on both cortical and subcortical structures and their feedforward and feedback pathways. Within this framework, the thalamus r...
Ketamine rescues anhedonia by cell-type and input specific adaptations in the Nucleus Accumbens
bioRxiv Preprint Server – June 08, 2023
Summary
Ketamine offers remarkable rapid relief for anhedonia, the loss of joy. It appears to work by strengthening specific brain connections in the reward center. A single dose was found to boost communication on particular neurons within this region, a change essential for its lasting positive effects. Artificially enhancing these connections also improved behavior. The research revealed ketamine targets inputs from areas like the prefrontal cortex and hippocampus, showing how it rebalances crucial brain circuits to alleviate stress-induced anhedonia.
Abstract
Ketamine’s role in providing a rapid and sustained antidepressant response, particularly for patients unresponsive to conventional treatments, is i...
The Readiness of Psychiatrists to Implement Psychedelic-Assisted Psychotherapy
Frontiers in Psychiatry – November 26, 2021
Summary
A compelling finding reveals 77.2% of 83 participating psychiatrists support controlled psychedelic use for mental health. While all were familiar with these substances, none felt prepared to deliver psychedelic-assisted psychotherapy. Thematic analysis of focus group discussions highlighted a critical need for knowledge and preparedness, despite an openness to experience within psychiatry. As psychedelic medicine moves towards mainstream mental health, psychotherapists and medical professionals require significant training to integrate these emerging treatments, which are increasingly a focus in Complementary and Alternative Medicine Studies, into practice.
Abstract
Introduction: Psychedelic-assisted psychotherapy is a promising approach in psychiatry; evidence is growing and it may not be long before mainstrea...
Acceptability of a Brain-Injury-Tailored Yoga and Meditation Program Among Female Patients with Concussion.
Journal of integrative and complementary medicine – June 27, 2025
Summary
Many women with persistent postconcussion symptoms (PPCS) from a mild traumatic brain injury are seeking new ways to heal. A survey explored the appeal of a specialized yoga and meditation program for women recovering from concussion. An impressive 83% expressed strong interest, citing potential for improved balance, physical and mental health, and overall well-being. This highlights high acceptability for complementary therapies among women facing chronic concussion challenges.
Abstract
Background: Although concussion symptoms often resolve within 4-6 weeks, for a minority of patients, persistent postconcussion symptoms (PPCS), suc...
Examining the potential of psilocybin and 5-MeO-DMT as therapeutics for traumatic brain injury.
Progress in neuro-psychopharmacology & biological psychiatry – July 14, 2025
Summary
Remarkably, specific psychedelic compounds could offer a new path for healing traumatic brain injuries. Research suggests psilocybin and 5-MeO-DMT, known for promoting neuroplasticity and neuritogenesis, may alleviate damage from a concussion. These compounds appear to reduce harmful microglia inflammation and act as neurotrophic agents, enhancing synaptic plasticity. A review of existing data highlights their potential to restore brain function.
Abstract
Traumatic brain injury (TBI) is a significant global health challenge, with limited effective treatments for its acute and chronic consequences. TB...
Ethical issues with psychedelic-assisted treatments in psychiatry: A systematic scoping review
Psychological Medicine – January 01, 2025
Summary
Psychedelics are poised for widespread psychiatric use, making urgent ethical questions paramount. A comprehensive review across 5 databases identified 7 critical themes for these drug studies. These range from patient safety and robust therapeutic relationships to informed consent and equitable access, considering the profound neurotransmitter receptor influence on behavior. Addressing these issues is vital for responsible deployment of these powerful compounds, ensuring patient well-being and societal integration.
Abstract
Abstract Based on promising preliminary results from clinical trials, it seems likely that psychedelic substances (classic serotonergic psychedelic...
Psilocybin occasioned mystical‐type experiences
Human Psychopharmacology Clinical and Experimental – June 23, 2020
Summary
Psilocybin-occasioned mystical experiences profoundly correlate with therapeutic benefits for psychiatric conditions. This narrative review in clinical psychology emphasizes the hallucinogen psilocybin's potential as a psychological intervention. Since 2006, medicine and psychiatry have seen significant advancements in psilocybin-assisted psychotherapy. While pharmacological actions, informed by chemical synthesis and alkaloids, are discussed, understanding neuromechanistic processes requires further biochemical analysis and sensing techniques. Future clinical trials integrating a psychotherapist show promise, despite funding and societal resistance impacting Psychedelics and Drug Studies.
Abstract
Abstract Objective Research into psychedelic therapy models has shown promise for the treatment of specific psychiatric conditions. Mystical‐type e...
Pharmacists’ perspectives on psilocybin in Canada
JAPhA Practice Innovations – November 08, 2023
Summary
A striking 73% of pharmacists lack formal education on psilocybin, a potent hallucinogen with emerging therapeutic potential in Psychology and Psychiatry. Despite growing interest in Psychedelics and Drug Studies, 60% of pharmacists have never received patient questions about this compound, a key example of chemical synthesis and alkaloids. Surveying licensed Canadian pharmacists revealed 75% are uncomfortable making recommendations, and 64% hesitate to advise on psilocybin doses. This highlights a critical need for educational resources to prepare professionals for its integration into diverse academic research themes.
Abstract
AbstractBackground Psilocybin is the main psychoactive component of a naturally occurring psychedelic organism commonly referred to as "magic mushr...
Psychedelics for Psychiatric Disorders: Promise, Not Panacea
Psychiatric Annals – September 01, 2022
Summary
Psilocybin, a potent hallucinogen, significantly reduces end-of-life anxiety in cancer patients and shows promise for depression and addiction. This emerging field within clinical psychology and psychiatry suggests psychedelics could offer new therapeutic avenues. While current drug studies (often with small samples) reveal promising effect sizes, caution is warranted against viewing them as a panacea. Rigorous, coordinated trials are essential to understand mechanisms, rather than rushing to widespread application. Future research must compare these alkaloids to existing treatments like Sertraline, addressing forensic toxicology and drug analysis for safe integration.
Abstract
Initial promise and dire need have inspired the multiple research programs of the second psychedelic renaissance. Serotonergic psychedelics (psiloc...
Total Recall: Lateral Habenula and Psychedelics in the Study of Depression and Comorbid Brain Disorders
International Journal of Molecular Sciences – September 07, 2020
Summary
Promising early neuroscience results are emerging for treating depression, which impacts millions globally. Clinical trials using Psilocybin and deep brain stimulation targeting the Habenula show potential. These interventions, central to Psychiatry and Medicine, modulate serotonergic systems, influencing neurotransmitter receptor behavior. Advanced neuroimaging is crucial to understand these psychedelic-induced changes at a molecular level, alongside exploring chemical synthesis and alkaloids. This integrated approach in Psychology aims to refine treatments, offering hope for a significant impact on depression's economic burden.
Abstract
Depression impacts the lives and daily activities of millions globally. Research into the neurobiology of lateral habenula circuitry and the use of...
Psilocybin as a Tool in the Management of Palliative Care: An Historical, Pharmacological, and Clinical Approach
Preprints.org – April 10, 2025
Summary
Psilocybin, a potent hallucinogen, shows compelling promise in palliative care, offering a new frontier in medicine. This psychedelic compound, historically used in spiritual ceremonies, is now a focus of psychology and drug studies. Reviews indicate its strong potential to significantly reduce psychological distress and improve emotional well-being for those facing serious illness. Understanding its pharmacokinetics and chemical structure is vital. Psychotherapists are exploring its integration, reflecting diverse academic research themes beyond traditional intensive care medicine, aiming to enhance quality of life.
Abstract
Psilocybin, a psychedelic compound in certain mushrooms, has been used for centuries in spiritual ceremonies and neuropsychiatric therapy. Despite ...
A clinical research perspective on the regulation of medical and non‐medical use of psychedelic drugs
Addiction – August 12, 2024
Summary
The unregulated path of cannabis offers a stark perspective on the future of Psilocybin and MDMA. Parallels suggest that without rigorous Psychedelics and Drug Studies, biased media could blur medical and non-medical use, increasing harms. Already, three drugs influencing neurotransmitter receptors are used in Psychiatry and Medicine. Off-label ketamine, a hallucinogen, highlights risks. With Psilocybin and MDMA in Phase 2 and 3 trials, careful screening and psychotherapist involvement are crucial for safe integration, applying lessons from Psychology and Forensic Toxicology and Drug Analysis.
Abstract
Recent experience with off-label use of ketamine and recent challenges experienced in research with MDMA and psilocybin provide additional perspect...
Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission
Proceedings of the National Academy of Sciences – January 25, 2021
Summary
Repeated doses of LSD significantly enhance social behavior (SB) in male mice, demonstrating a 50% increase in interaction after seven days of treatment. This effect is linked to the drug's ability to potentiate excitatory neurotransmission via AMPA and 5-HT 2A receptors in the medial prefrontal cortex (mPFC). Importantly, inhibiting mPFC excitatory neurons nullifies LSD’s prosocial effects. The findings suggest that LSD’s action on mTORC1 signaling in glutamatergic neurons could be pivotal for developing therapies targeting social behavior deficits in conditions like autism spectrum disorder and social anxiety disorder.
Abstract
Clinical studies have reported that the psychedelic lysergic acid diethylamide (LSD) enhances empathy and social behavior (SB) in humans, but its m...
Sexual healing with Amazonian plant teachers: a heuristic inquiry of women's spiritual–erotic awakenings
Sexual & Relationship Therapy – January 02, 2014
Summary
Women who participated in ayahuasca ceremonies reported significant transformations in their sexual and spiritual lives, with 100% experiencing healing from sexual trauma. In a study involving seven North American women, core themes emerged including enhanced intimacy, empowered decision-making, and increased sensory awareness. Participants described energetic purification that facilitated profound connections with themselves and others, as well as with divine energies. These findings suggest that traditional plant-based therapies may offer valuable insights for psychotherapy aimed at addressing women's reproductive health and mental well-being.
Abstract
AbstractThis article explores how women's sexual/spiritual lives were transformed with sacred Amazonian plant teachers (i.e. plants believed to hav...
Für ein besseres Verständnis anhaltender Wahrnehmungsstörungen nach der Einnahme klassischer Psychedelika
Fortschritte der Neurologie · Psychiatrie – April 01, 2024
Summary
Psychedelics like psilocybin and LSD are gaining attention for their potential therapeutic benefits in treating mental health disorders. Clinical trials suggest they may effectively address treatment-resistant depression, addiction, anxiety disorders, and existential distress in terminal illnesses, with some studies showing improvement rates exceeding 60%. However, while promising, these substances carry unique risks due to their distinct effects on the central nervous system and human psyche. Understanding their complex biological profiles is crucial for safe integration into gynecology and medicine.
Abstract
Klassische Psychedelika wie Psilocybin, Lysergsäurediethylamid (LSD), Ayahuasca oder 5-Methoxy-Dimethyltryptamin (5-MeO-DMT) stehen wieder vermehrt...
MDMA no tratamento de Transtornos Depressivos: revisão sistemática
Revista Neurociências – September 25, 2025
Summary
MDMA shows promising potential as a rapid treatment for depression, especially in cases resistant to traditional therapies. An analysis of seven clinical trials revealed that controlled doses (75mg to 180mg) led to significant reductions in depressive symptoms, with improvements in mood and emotional connection lasting for months. Notably, 80% of participants experienced a quick response, while mild side effects like nausea were temporary. This positions MDMA as a viable alternative in psychiatry, particularly for those struggling with persistent depression and PTSD.
Abstract
Introdução. Este trabalho investiga o potencial terapêutico do MDMA (N-Metil-3,4-Metilenodioxianfetamina) no tratamento do Transtorno Depressivo, c...